| Literature DB >> 35293942 |
Ligia Fernanda Ferraz1, Cintia Rabelo E Paiva Caria2, Raquel de Cássia Santos3, Marcelo Lima Ribeiro3, Alessandra Gambero4.
Abstract
PURPOSE: To evaluate how the induction of liver damage by ischemia and reperfusion affects the adipose tissue of lean and obese mice.Entities:
Mesh:
Year: 2022 PMID: 35293942 PMCID: PMC8923565 DOI: 10.1590/acb370105
Source DB: PubMed Journal: Acta Cir Bras ISSN: 0102-8650 Impact factor: 1.388
Primer sequences used in the study.
|
|
| |
|---|---|---|
| Actb | forward primer |
|
| Il6 | forward primer |
|
| Il1b | forward primer |
|
| Tnf | forward primer |
|
| Lep | forward primer |
|
| Adipoq | forward primer |
|
Figure 1Hepatic and systemic effects in response to 30 min of hepatic ischemia followed by 6 h of hepatic reperfusion in lean and obese mice. Aspartate aminotransferase (AST) serum levels (a), interleukin-1β serum levels (b) and myeloperoxidase (MPO) activity in liver samples of lean and obese mice after liver IRI or sham procedure (n = 4–5). *p < 0.05 liver IRI vs. sham group.
Figure 2Cytometry analysis of cellular infiltration observed in the stromal vascular fraction of visceral adipose tissue from lean and obese mice after liver IRI or sham procedure (n = 4–5). (a) Total leukocytes; (b) Neutrophils; (c) Monocytes; (d) Macrophages; (e) T-lymphocytes; f. B-lymphocytes. *p < 0.05 liver IRI vs. sham group.
The mouse inflammatory cytokines and receptors RT2 profiler PCR array from lean liver IRI mice vs. lean sham-operated mice.
|
|
|
|
|---|---|---|
|
| Duffy blood group, chemokine receptor | 2.83 |
|
| Chemokine binding protein 2 | 5.47 |
|
| Chemokine (C-X-C motif) receptor 7 | 3.24 |
|
| Chemokine (C-C motif) receptor-like 1 | 2.81 |
|
| Complement component 5a receptor 1 | 5.01 |
|
| Chemokine (C-C motif) ligand 1 | 5.01 |
|
| Chemokine (C-C motif) ligand 11 | 0.21 |
|
| Chemokine (C-C motif) ligand 12 | 1.68 |
|
| Chemokine (C-C motif) ligand 17 | 7.33 |
|
| Chemokine (C-C motif) ligand 19 | 6.99 |
|
| Chemokine (C-C motif) ligand 2 | 5.02 |
|
| Chemokine (C-C motif) ligand 20 | 6.42 |
|
| Chemokine (C-C motif) ligand 22 | 6.83 |
|
| Chemokine (C-C motif) ligand 24 | 7.13 |
|
| Chemokine (C-C motif) ligand 25 | 2.88 |
|
| Chemokine (C-C motif) ligand 26 | 6.50 |
|
| Chemokine (C-C motif) ligand 28 | 5.84 |
|
| Chemokine (C-C motif) ligand 3 | 3.87 |
|
| Chemokine (C-C motif) ligand 4 | 4.29 |
|
| Chemokine (C-C motif) ligand 5 | 3.37 |
|
| Chemokine (C-C motif) ligand 6 | -1.87 |
|
| Chemokine (C-C motif) ligand 7 | 5.44 |
|
| Chemokine (C-C motif) ligand 8 | 3.33 |
|
| Chemokine (C-C motif) ligand 9 | 2.40 |
|
| Chemokine (C-C motif) receptor 1 | 4.23 |
|
| Chemokine (C-C motif) receptor 10 | 4.85 |
|
| Chemokine (C-C motif) receptor 1-like 1 | 4.66 |
|
| Chemokine (C-C motif) receptor 2 | 1.82 |
|
| Chemokine (C-C motif) receptor 3 | 5.21 |
|
| Chemokine (C-C motif) receptor 4 | 6.74 |
|
| Chemokine (C-C motif) receptor 5 | 3.51 |
|
| Chemokine (C-C motif) receptor 6 | 5.12 |
|
| Chemokine (C-C motif) receptor 7 | 5.78 |
|
| Chemokine (C-C motif) receptor 8 | 5.93 |
|
| Chemokine (C-C motif) receptor 9 | 4.72 |
|
| Chemokine (C-C motif) receptor-like 2 | 4.67 |
|
| Chemokine-like receptor 1 | 3.26 |
|
| CKLF-like MARVEL transmembrane domain containing 2A | 5.07 |
|
| CKLF-like MARVEL transmembrane domain containing 3 | 2.11 |
|
| CKLF-like MARVEL transmembrane domain containing 4 | 0.62 |
|
| CKLF-like MARVEL transmembrane domain containing 5 | 6.16 |
|
| CKLF-like MARVEL transmembrane domain containing 6 | 0.84 |
|
| Chemokine (C-X3-C motif) ligand 1 | 3.87 |
|
| Chemokine (C-X3-C) receptor 1 | 5.13 |
|
| Chemokine (C-X-C motif) ligand 1 | 4.02 |
|
| Chemokine (C-X-C motif) ligand 10 | 4.09 |
|
| Chemokine (C-X-C motif) ligand 11 | 2.76 |
|
| Chemokine (C-X-C motif) ligand 12 | -0.23 |
|
| Chemokine (C-X-C motif) ligand 13 | 5.99 |
|
| Chemokine (C-X-C motif) ligand 14 | 2.41 |
|
| Chemokine (C-X-C motif) ligand 15 | 6.29 |
|
| Chemokine (C-X-C motif) ligand 16 | 3.13 |
|
| Chemokine (C-X-C motif) ligand 2 | 4.01 |
|
| Chemokine (C-X-C motif) ligand 3 | 6.41 |
|
| Chemokine (C-X-C motif) ligand 5 | 1.26 |
|
| Chemokine (C-X-C motif) ligand 9 | 4.10 |
|
| Chemokine (C-X-C motif) receptor 1 | 4.98 |
|
| Chemokine (C-X-C motif) receptor 2 | 6.10 |
|
| Chemokine (C-X-C motif) receptor 3 | 5.42 |
|
| Chemokine (C-X-C motif) receptor 4 | 3.48 |
|
| Chemokine (C-X-C motif) receptor 5 | 5.41 |
|
| Chemokine (C-X-C motif) receptor 6 | 4.37 |
|
| Formyl peptide receptor 1 | 4.74 |
|
| G protein-coupled receptor 17 | 4.08 |
|
| Hypoxia inducible factor 1, alpha subunit | 1.08 |
|
| Interferon gamma | 5.15 |
|
| Interleukin 16 | 3.70 |
|
| Interleukin 1 beta | 4.06 |
|
| Interleukin 4 | 5.29 |
|
| Interleukin 6 | 5.93 |
|
| Integrin alpha M | 1.69 |
|
| Integrin beta 2 | 1.67 |
|
| Mitogen-activated protein kinase 1 | 0.21 |
|
| Mitogen-activated protein kinase 14 | 3.17 |
|
| Platelet factor 4 | 3.60 |
|
| Pro-platelet basic protein | 7.33 |
|
| Slit homolog 2 (Drosophila) | 3.35 |
|
| Transforming growth factor, beta 1 | 1.01 |
|
| Toll-like receptor 2 | 4.60 |
|
| Toll-like receptor 4 | 3.29 |
|
| Tumor necrosis factor | 9.10 |
|
| Thymidine phosphorylase | 4.61 |
|
| Chemokine (C motif) ligand 1 | 4.98 |
|
| Chemokine (C motif) receptor 1 | 4.27 |
Figure 3Illustrative scatter plot demonstrating gene expression of VAT from obese mice submitted to liver IRI normalized by gene expression of VAT from obese sham-operated mice. The central line indicates unchanged gene expression. The dotted lines indicate the selected fold regulation threshold. Data points beyond the dotted lines in the upper left and lower right sections meet the selected fold regulation threshold.
Figure 4Alterations in the expression of genes encoding cytokines, chemokines and their receptors in adipose tissue (a) Illustrative scatter plot demonstrating the gene expression listed on Table 2 of VAT from lean mice submitted to liver IRI normalized by gene expression of VAT from sham-operated mice. The central line indicates unchanged gene expression. The dotted lines indicate the selected fold regulation threshold. Data points beyond the dotted lines in the upper left and lower right sections meet the selected fold regulation threshold. (b) Il6, Il1b, Tnf, Lep and adipoq mRNA expression validated by RT-qPCR in VAT of sham and liver IRI mice (n = 4). *p < 0.05 liver IRI vs. sham group.
Figure 5Observed alterations in intestinal permeability after liver IRI or sham procedures in lean mice. (a) Endotoxin serum levels; (b) FITC-dextran serum levels; (n = 4–5). *p < 0.05 liver IRI vs. sham group.